Company Overview - Nanwei Medical's closing price on July 4 was 70.52 yuan, an increase of 3.46%, with a rolling PE ratio of 23.21, marking a new low in 87 days, and a total market capitalization of 13.247 billion yuan [1] - The company specializes in the research, development, manufacturing, and sales of minimally invasive medical devices, with key products including biopsy, hemostasis, closure, EMR/ESD, dilation, ERCP, EUS/EBUS devices, ablation instruments, disposable imaging systems, and related consumables [1] Financial Performance - For Q1 2025, Nanwei Medical reported revenue of 699 million yuan, a year-on-year increase of 12.75%, and a net profit of 161 million yuan, also up 12.18%, with a gross profit margin of 65.69% [1] Shareholder Information - As of March 31, 2025, the number of shareholders in Nanwei Medical was 13,313, an increase of 639 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 51.05, with a median of 36.62, placing Nanwei Medical at the 50th position in the industry ranking [1][2] - The static PE ratio for Nanwei Medical is 23.94, and the price-to-book ratio is 3.32 [2]

Group 1 - The core viewpoint of the articles highlights Jianghe Group's current stock performance, with a closing price of 6.18 yuan and a decline of 1.12%, resulting in a rolling PE ratio of 11.66 times and a total market value of 7.002 billion yuan [1] - Jianghe Group ranks 21st in the decoration and renovation industry, which has an average PE ratio of 43.83 times and a median of 42.46 times [1] - As of the first quarter of 2025, 12 institutions hold shares in Jianghe Group, including 8 funds, with a total holding of 54,503.88 million shares valued at 3.341 billion yuan [1] Group 2 - Jianghe Group's main business segments include construction decoration and healthcare, with key products such as building curtain walls, photovoltaic buildings, interior decoration, interior design, and ophthalmic medical services [1] - The latest performance report for the first quarter of 2025 shows that the company achieved an operating income of 4.203 billion yuan, a year-on-year increase of 2.87%, while net profit was 144 million yuan, reflecting a year-on-year decrease of 20.53%, with a sales gross margin of 15.03% [1]

Group 1 - The core viewpoint of the articles indicates that Kaichuang International's stock price has decreased by 3.80%, with a current PE ratio of 38.46 and a total market capitalization of 2.559 billion yuan [1][2] - The average PE ratio for the agriculture, animal husbandry, and fishery industry is 43.09, with a median of 43.51, positioning Kaichuang International at the 53rd rank within the industry [1][2] - As of March 31, 2025, the number of shareholders for Kaichuang International has increased to 18,479, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Kaichuang International primarily engages in deep-sea fishing, seafood processing, sales, and related trade, with key products including tuna, canned foods, and fish fillets [1] - In the first quarter of 2025, the company reported a revenue of 583 million yuan, reflecting a year-on-year growth of 5.04%, and a net profit of 12.9191 million yuan, which is a significant increase of 70.33%, with a sales gross margin of 32.46% [1]

Group 1 - The core viewpoint of the news highlights that Tailin Bio's stock closed at 21.03 yuan, down 1.73%, with a rolling PE ratio of 238.08 times, and a total market value of 2.549 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical device industry is 51.05 times, with a median of 36.62 times, placing Tailin Bio at the 117th position [1][3] - The net outflow of main funds for Tailin Bio on July 4 was 2.3092 million yuan, with a total outflow of 23.9872 million yuan over the past five days [1] Group 2 - Tailin Bio specializes in the research, production, and promotion of products related to microbiological testing and pollution control, innovative drug development, and process analysis, serving various industries including biomedicine, healthcare, food and beverage, and environmental protection [2] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 66.939 million yuan, a year-on-year decrease of 16.33%, and a net profit of 3.5282 million yuan, down 39.93%, with a sales gross margin of 49.27% [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of MacAudie, indicating a relatively high PE ratio compared to the industry average [1][2] - As of July 4, MacAudie's closing price was 15.67 yuan, with a PE ratio of 49.27 and a total market capitalization of 8.108 billion yuan [1] - The average PE ratio for the electrical equipment industry is 35.91, with a median of 38.13, placing MacAudie at the 103rd position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, MacAudie reported a revenue of 316 million yuan, reflecting a year-on-year increase of 5.91%, and a net profit of 34.88 million yuan, up 9.70% year-on-year [1] - The company's gross profit margin stands at 41.77% [1] - Eight institutions currently hold shares in MacAudie, with a total holding of 336.88 million shares valued at 5.596 billion yuan [1]

序号股票简称PE(TTM)PE(静)市净率总市值(元)8东华能源33.9033.661.34149.42亿行业平均 12.7911.501.211749.81亿行业中值29.3233.481.5955.79亿1ST新潮9.208.411.01218.30亿2中国海油 9.279.061.5912495.62亿3中国石油9.509.561.0115739.80亿4广汇能源13.6913.161.41389.76亿5中国石化 15.2213.690.826886.73亿6洲际油气22.4119.911.1297.09亿7泰山石油24.7333.303.0333.08亿9康普顿 41.3350.502.3527.59亿10广聚能源65.1870.302.4268.16亿11和顺石油86.5996.571.7128.26亿12岳阳兴长 101.1888.382.5755.79亿 来源：金融界 截至2025年一季报，共有11家机构持仓东华能源，其中其他8家、基金2家、券商1家，合计持股数 71487.21万股，持股市值68.27亿元。 东华能源股份有限公司的主营业务是公司需遵守《深圳证券交易所上市公司自律监管指引第3号 ...

Company Overview - New Mile Health Technology Group Co., Ltd. focuses on medical services and pharmaceutical industry, with a primary product line that includes medicines and medical products [1] - The company has over 20 years of experience in drug production, establishing a series of traditional Chinese medicine centered around the "Duyiwei" brand, which is recognized in the 2020 edition of the "Chinese Pharmacopoeia" [1] Financial Performance - For Q1 2025, the company reported a revenue of 796 million yuan, a year-on-year decrease of 16.49%, and a net profit of 25.65 million yuan, down 9.35% year-on-year, with a gross margin of 27.96% [1] - The current stock price is 2.17 yuan, reflecting a decline of 1.36%, with a rolling price-to-earnings (PE) ratio of 65.56 times [1] Market Position - The average PE ratio for the medical services industry is 41.66 times, with a median of 43.26 times, positioning New Mile at 34th place within the industry [2] - The company's total market capitalization is 7.351 billion yuan [2] Shareholder Information - As of June 10, 2025, New Mile has 64,494 shareholders, an increase of 419 since the last report, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Company Overview - The company, Boai New Kaineng Medical Technology Group Co., Ltd., specializes in fine chemicals and precision medicine, with key products including PVPK30, PVP-I, PVP series, and early cancer diagnosis services [1] - As of the first quarter of 2025, the company reported a revenue of 325 million yuan, a year-on-year decrease of 17.69%, and a net profit of 80.42 million yuan, down 33.75% year-on-year, with a gross profit margin of 44.07% [1] Market Position - The company's stock closed at 17.09 yuan, up 1.12%, with a rolling price-to-earnings (PE) ratio of 26.91 times, and a total market capitalization of 8.307 billion yuan [1] - In comparison to the chemical products industry, which has an average PE of 45.46 times and a median of 41.12 times, the company ranks 76th in terms of PE [1][2] Institutional Holdings - As of the first quarter of 2025, there are two institutions holding shares in the company, with a total of 18.8125 million shares held, valued at 319 million yuan [1]

Company Overview - Hunan Jingfeng Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and sales of pharmaceutical products, with a diverse product line including unique national insurance drugs [2] Financial Performance - For Q1 2025, the company reported revenue of 100 million yuan, a year-on-year decrease of 0.46%, and a net loss of approximately 11.9 million yuan, a significant decline of 960.04% compared to the previous year [3] - The gross profit margin for the company stands at 66.62% [3] Market Position - As of July 3, 2023, the company's stock closed at 5.87 yuan, down 1.34%, with a rolling price-to-earnings (PE) ratio of 36.49 times, compared to the industry average PE of 54.72 times and a median of 33.17 times, placing the company at the 95th position in the industry [1][3] - The total market capitalization of the company is 5.164 billion yuan [1] Shareholding Structure - As of the Q1 2025 report, two institutions hold shares in the company, with a total of 12,476.40 million shares valued at 558 million yuan [1]

Core Viewpoint - The company, Zhaoyan New Drug, has experienced a decline in stock price and revenue, while showing significant growth in net profit, indicating mixed performance in the current market environment [1]. Company Summary - Zhaoyan New Drug's closing stock price on July 2 was 21.95 yuan, down 1.57%, with a rolling PE ratio of 42.46 times and a total market capitalization of 16.451 billion yuan [1]. - The company operates primarily in non-clinical safety evaluation services for drugs, clinical research services, and sales of experimental animals and related products [1]. - For the first quarter of 2025, Zhaoyan New Drug reported revenue of 287 million yuan, a year-on-year decrease of 11.54%, while net profit reached 41.1195 million yuan, reflecting a year-on-year increase of 115.11%, with a gross profit margin of 28.61% [1]. Industry Summary - The average PE ratio for the medical services industry is 41.66 times, with a median of 43.69 times, placing Zhaoyan New Drug at the 29th position within the industry [1]. - As of the first quarter of 2025, 22 institutions held shares in Zhaoyan New Drug, including 20 funds, with a total holding of 72.9482 million shares valued at 1.484 billion yuan [1]. - The industry comparison shows that Zhaoyan New Drug's PE ratio is higher than the industry average but lower than the median, indicating a competitive yet challenging market position [2].